Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.67 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | CNR1 | P21554 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27905664 | 0.90 | RAB9A (0.58) | MEN1KMT2ARAB9AMAPTSMN1; SMN2 | |
| SCHEMBL4176742 | 0.84 | HDAC3 (0.61) | MEN1KMT2ARAB9ANPC1LMNA | |
| SCHEMBL8993463 | 0.84 | MAOA (0.83) | MEN1KMT2AMAOAMAOBCA12 | |
| SCHEMBL28327348 | 0.83 | MEN1 (0.69) | MEN1KMT2AMAOAMAOBTNIK | |
| SCHEMBL17976392 | 0.83 | ABAT (0.61) | MEN1KMT2AMAOAMAOBCA12 | |
| SCHEMBL545945 | 0.83 | SMN1; SMN2 (0.65) | MEN1KMT2AMAOAMAOBCA12 | |
| SCHEMBL27323392 | 0.82 | KLKB1 (0.50) | RAB9ANPC1MAPT | |
| SCHEMBL4167790 | 0.81 | CNR1 (0.60) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL4165737 | 0.81 | LOXL2 (0.59) | MEN1KMT2AMAOBCA12CA1 | |
| SCHEMBL28245373 | 0.81 | KLKB1 (0.49) | RAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090004185-A1 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | WYETH (US) | 2009-01-01 | — | — | US | disclosed |
| WO-2008086462-A2 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | WYETH (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090004185-A1 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | TCF4, CTNNB1, TCF7 | MEN1 3943/4885KMT2A 1372/4885MAOA 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.